MajesTEC-2: This phase I study is trying to understand how safe and tolerable, and determine the optimal dose level, of a targeted therapy (teclistamab) when it is administered in different combinations with other cancer drugs in people with multiple myelomaA Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Summary

This non-randomised, open-label study has six experimental arm all evaluating different treatment regimens. In Experimental Arm A, participants will receive a treatment regimen of Teclistamab + Daratumumab + Pomalidomide. In Experimental Arm B, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (21-day Cycles). In Experimental Arm C, participants will receive Teclistamab + Nirogacestat. In Experimental Arm D, participants will receive Teclistamab + Lenalidomide. In Experimental Arm E, participants will receive Teclistamab + Daratumumab + Lenalidomide. In Experimental Arm F, participants will receive Teclistamab + Daratumumab + Lenalidomide + Bortezomib (28-day Cycles).